State governments use a system of open formularies known as preferred drug lists in Medicaid and other programs that purchase pharmaceuticals in order to control costs. The safety, efficacy, and cost effectiveness of new treatments are compared to existing ones, and the best drugs are included in the PDL. Federal trade policy seeks to limit this type of evidence-based pricing.
Trade, Policy and IP
Last week, PIJIP and the Academy of Exchange and Judicial Studies (AIEJ), Buenos Aires, Argentina, hosted a week-long training on the topic of pharmaceutical patent litigation.Read more
For the sixth year in a row, WCL alum Andres Izquierdo has been ranked by the British Global Lawyer Ranking firm “Chambers and Partners” as a top Intellectual Property Attorney for Latin American.Read more
PIJIP is pleased to announce that Professor Ruth Okediji will give the 8th Annual Peter A. Jaszi Distinguished Lecture on Intellectual Property on October 10, 2019, at 6pm. Okediji is the Jeremiah Smith, Jr, Professor of Law at Harvard Law School and Co-Director of the Berkman Klein Center.Read more
The Program on Information Justice and Intellectual Property (PIJIP) is the internationally recognized intellectual property and information law research and academic program of American University Washington College of Law (AUWCL). PIJIP’s academic programs, including our new LL.M. degree in Intellectual Property, and a first in the nation IP Clinic, offer an unparalleled course of study in the fields of intellectual property and information law. PIJIP’s faculty is among the most prolific and engaged IP faculties in the world. Full-time faculty teach courses in every major topic of the field, including Copyright, Patent, Trademark, Trade Secret, Cyberlaw, and a full array of international intellectual property law courses.